Aortic valve disease is common in the United States (U.S.), occurring in 2-5% of the elderly population. 1 When untreated, symptom progression is both rapid [2] [3] [4] and lethal, [5] [6] [7] [8] with a median survival of less than two years in those with heart failure symptoms. 9 Medical therapy is largely ineffective for the chronic management of aortic valve disease, and valve replacement remains the standard of care in patients with an acceptable risk profile.
Among the oldest patients and those with a high burden of comorbidities, the perioperative risk of surgical aortic valve replacement (AVR) is often perceived to outweigh the potential long-term benefits, with a perception of high operable risk accounting for nearly half (48%) of all non-operated patients with symptomatic aortic stenosis. 10 While the perioperative risk associated with AVR has been well studied, 11, 12 the long-term outcomes following open AVR have not been well described, making an accurate assessment of the benefits of open AVR challenging in this population.
Transcatheter delivery of aortic valve prostheses offers a potential treatment option in high-risk patients and has been shown at one-year follow-up to be both superior to medical therapy in non-operable patients 13 and non-inferior to open valve replacement in high-risk patients. 14 As long-term transcatheter aortic valve replacement (TAVR) outcomes accrue, the establishment of a robust surgical benchmark of long-term survival following open AVR is of increasing importance to inform prognosis and aid clinical and economic evaluations of new technologies.
To better inform this discussion, we linked clinical data from more than 1,000
participating centers within the Society of Thoracic Surgeons (STS) network to Medicare administrative inpatient claims to create a large, well-characterized longitudinal cohort of elderly patients representative of those selected for AVR in the U.S. and Canada over the past two isk associated with AVR has been well studied, 11, 12 the long-term outcomes foll llow ow owin ing g g op op open en en AVR have not been well described, making an accurate assessment of the benefits of open AVR ch hal al alle le len ng ngin in ing g g in in in thi hi his s s po p pulation.
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Methods
The STS Adult Cardiac Surgery Database (ACSD) is among the most robust clinical data repositories in the world, including more than 300 data elements describing patient demographics, comorbidities, and operative outcomes. The database began in 1989 with a mission to improve the quality of cardiac surgical procedures at participating centers. The ACSD now represents more than 1,000 participants throughout North America, including over 90% of cardiac surgery centers in the U.S. 15 The ACSD maintains high standards of data accuracy, with a 96% correlation between ACSD data and that obtained through independent chart abstraction. 16 In partnership with the Duke Clinical Research Institute's (DCRI's) Cardiovascular Outcomes
Research Center, the STS has developed and validated a valve-specific morbidity and mortality operative risk calculator 11 -a tool that has been used to identify high-risk patients for inclusion in recent TAVR clinical trials.
13,14

Study Population
For the purposes of this study, STS ACSD records from 266,525 operations involving AVR procedures (with or without concomitant coronary artery bypass grafting [CABG] ) in elderly patients (65+ years) were identified for linkage to Part A Medicare Provider and Analysis Review (MedPAR) insurance claims files ( Figure 1 ). Records were excluded if they involved:
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Patient Subgroups
Since long-term outcomes were expected to vary according to the burden of specific comorbidities, several patient subgroups were prospectively identified for analysis. For all analyses, patients were categorized by procedure type (e.g., isolated AVR, AVR + CABG) and age (65-69 years, 70-79 years, 80 years). Other specific patient subgroups were categorized econd, more contemporary Medicare-linked cohort was identified, including 103 03 3,5 5 500 00 0 p p pat at atie ie ient nt n s s undergoing procedures between 1999 and 2007 (maximum 10 years follow-up) with a minimum fo oll ll low ow ow-u -up p p of of of o one e e y y yea e r. The 1991-2007 cohort wa wa as s s u u used to evalua ate te e age ge e-s -s -str tratified very long-term outc c com o es follo ow wi w n n ng A A AVR VR VR, wh wh whi il ile e th th the e e 1 19 99 9 99-2 200 0 07 c co on n ntem m mp po por rar ry ry c coh oh hor ort t wa wa was u us use ed ed t to o o ev ev val l alua ua ate t te i i in-n-nm m ho hosp sp spit it ital al a c com om ompl plic icat atio ion ns s a a and nd m m med ed dia ia ian n n s sur ur rvi vi viva va val l l st tra ra rati tif f fie ed ed b b by y y th th the e e ST ST STS S S PR PR PROM OM M a and nd nd h h hig ig gh h-h-r ri risk sk k c cl li lini nic ca cal l l features. Clin nic ic ical al a c c cha ha h ra ra ract c c er r ris is i ti ti tics s s an an a d d d op p per er erat at a iv iv ive e e ou ou outc tc com om omes es s w w wer er ere e e ta ta tabu bu bula la late te ted d d an an and d d ar ar re e e pr pr p es es esen e e ted for according to the STS data definitions for the following comorbidities: lung disease, left ventricular dysfunction (left ventricular ejection fraction [LVEF] >30%, 30%), renal failure, and prior cardiac operation (0, 1). According to the v2.52 STS ACSD data specifications, lung disease was classified as follows: none, mild (forced expiratory volume in 1 second [FEV1] 60% to 75% of predicted and/or on chronic inhaled or oral bronchodilator therapy), moderate (FEV1 50% to 59% of predicted and/or on chronic steroid therapy aimed at lung disease), and severe (FEV1 <50% predicted and/or room air pO2 <60 or room air pCO2 >50). Renal failure was defined as: (1) a documented history of renal failure; and/or (2) a history of creatinine >2.0.
Prior renal transplant patients are not included as pre-operative renal failure unless since transplantation their creatinine has been or is currently >2.0. For this analysis, the renal failure cohort was subdivided into those with or without a pre-operative need for dialysis. A STS PROM score was calculated using clinical data for each patient undergoing AVR between January 1999 and December 2007, and the cohort was stratified as low-risk (<5% STS PROM), moderate-risk (5-9% STS PROM), and high-risk ( 10% STS PROM) using previously established cutoffs. 13, 14 Data necessary for classification of STS PROM was missing in <5% of patients in the contemporary cohort. Consistent with the standards of the STS PROM online calculator, missing values for body surface area were imputed to the gender-specific median value, and those for LVEF were imputed to the gender-specific median value for patients with documented congestive heart failure or a "normal" value (i.e., LVEF=50%) for those without heart failure.
Missing values for the remaining categorical risk factors were defaulted to their most common value (i.e., "no disease").
Study Endpoint
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Statistical Analysis
Demographics, comorbidities, and in-hospital outcomes were tabulated according to the procedure performed (e.g., isolated AVR or AVR + CABG) for both the complete AVR cohort (1991-2007, Table 1 ) and the contemporary AVR subgroup (1999-2007, Table 2 ). In addition, to aid with assessment of the representativeness of the Medicare-linked STS ACSD AVR cohort as compared with the overall Medicare-eligible STS ACSD AVR cohort, characteristics of each are presented in Table 1 . Baseline characteristics were summarized as percentages for categorical variables and as medians with 25th and 75th percentiles (interquartile range, IQR) for continuous variables.
Survival probabilities were calculated using the product-limit method of Kaplan and Meier, 19 and median survival was calculated as the time beyond which 50% of the cohort was expected to survive. Subgroup comparisons of Kaplan-Meier survival probabilities were made using log-rank tests. An estimate of discrimination of the STS PROM for 10-year survival in the contemporary AVR subgroup was calculated using Harrell's generalized c-statistic for time-toevent data with censoring. SAS statistical software (version 9.1; SAS Institute, Cary, NC) was used for all calculations.
Results
Study Population
A cohort of 145,911 patients who underwent AVR from 1991 to 2007 at 1,026 centers were compared with the overall Medicare-eligible STS ACSD AVR cohort, characteri rist stic ic cs of of of e e eac ac ach h h ar a e presented in Table 1 . Baseline characteristics were summarized as percentages for categorical va ari ri iab ab able le les s an an and d d as s m m med edians with 25th and 75th per r rce ce c n n ntiles (interqua art r r ile e ra ra ran n nge, IQR) for continuous a a a v vari i iab a les.
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In-hospital Outcomes
In-hospital outcomes are presented in Table 2 for the contemporary Medicare-linked AVR cohort. The incidence of in-hospital complications, the post-operative length of stay, and the operative mortality increased as the contemporary cohort was restricted to patients with a STS PROM 5% (moderate-and high-risk) and 10% (high-risk cohort).
Long-term Survival following Open AVR
Long-term survival following open AVR is presented in Figure 2 for the full Medicare-linked (Table 3) .
Several specific patient characteristics (e.g., lung disease, left ventricular dysfunction, renal failure, and prior cardiac operation) were associated with worse long-term survival following AVR (p<0.0001 comparing the survival probabilities of patients with 'no disease' and 'no prior operation' vs. those with disease or prior operation) ( Tables 4 and 5 ). Both severe lung disease and renal failure (especially dialysis-dependent renal failure) were associated with a particularly poor long-term prognosis.
The long-term survival of patients in the contemporary AVR cohort is presented in Sever ral al al s s spe pe peci ci c fi fi ic c pa pati ti tien en ent ch ch char ar rac a a te te teri ri rist st s ic ic ics s s (e (e (e.g .g .g., ., l l lun ung g g di di dise se seas as ase, e, e lef ef eft t ve ve vent nt ntri ri ricu cu ula la lar r r dy dy dysf sf sfun u ction, Among moderate-and high-risk patients, patient age had limited incremental impact on longterm survival.
The expected survival in symptomatic patients with aortic valve disease is in the range of two to three years. 9 In light of this relatively short life-expectancy, the long-term survival in elderly patients undergoing AVR or AVR + CABG is excellent. Although the median survival following isolated AVR in patients under 70 years of age was lower than that of a similarly aged U.S. population (13 years observed versus 16 years expected), 21 the median survival of patients 70 years of age or older was nearly equivalent to that of their peers 21 (9 years vs. 10 years for 70-
Discussion
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These findings are similar to the 20 year experience recently reported among octo-and nanogenarians undergoing open heart surgery at a single German hospital center-a cohort that included 303 isolated AVR and 297 AVR + CABG procedures. 22 Among isolated AVR patients, the median survival was 6.1 years, which is nearly identical to survival reported here. As in our study, no difference was observed between median survival in the isolated AVR cohort and that of the age-and sex-matched population. Also, as in our study, actuarial survival at 10 years in the AVR + CABG cohort was lower than in the isolated AVR cohort (21.6% vs. 18.2%, p=0.02). . 23 Finally, in the Nkomo analysis, the Olmsted County cohort included a large subgroup (28%) of patients under 65 years of age-a group that is anticipated to have a lower observed survival than expected based on our data.
In addition to age, several specific risk factors (e.g., lung disease, left ventricular dysfunction, renal failure, prior cardiac operation) were associated with reduced long-term survival, which is a similar finding to the results reported by others. [24] [25] [26] Both severe lung disease and renal failure were associated with a nearly 50% lower observed 8-year survival when . Se e eco co cond nd nd, in in in a a add dd ddit it itio io on n n to to to p p pat tie ie ient nt nts s s wi wi with th th a a aor or orti ti tic c c va va valv lv lve e di di dise se seas as ase, e e the compared with patients without these comorbidities, whereas left ventricular dysfunction and prior cardiac operations were associated with a roughly 25% lower observed 8-year survival.
Patients with dialysis-dependent renal failure had a particularly poor prognosis following isolated AVR, with a median survival of 2.5 years, 2.0 years, and 0.7 years among patients aged 65-69, 70-79, and 80+ years, respectively. Importantly, this report expands on prior work by providing age-and comorbidity-stratified estimates of survival (median, 1 year, 4 years, 8 years)
that can be used directly for prognosis and to determine therapeutic options.
As shown in Figure 3 , the STS PROM was an effective means of differentiating long-
term survival following open AVR. These results build on the single-center experience of Dewey et al., which reported superior mid-term (4.2 ± 2.7 years, n=638) risk prediction of the STS PROM compared with both the EuroSCORE (additive and logistic) and Ambler Risk Score, especially among high-risk patients. 27 In this multi-center cohort, we have demonstrated excellent differentiation of long-term risk among elderly patients using the STS PROM. Within the moderate-and high-risk strata of STS PROM, the observed operative mortality was similar across the spectrum of age, suggesting that the practice of "upgrading" clinical risk beyond that reported by the STS PROM calculator for the oldest patients is not necessary in these risk groups. Among low-risk patients, long-term survival was further stratified by patient age;
however, the median survival among the oldest patients (80+ years old) with a low STS PROM was greater than seven years, both with and without concomitant CABG.
Since these results may serve as a contemporary benchmark to evaluate new therapies 
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Denominator File for ascertainment of long-term survival has known limitations inherent to the data source, 18 including an underreporting of mortality in some patient subgroups. This may have resulted in an overestimate of the true long-term survival of patients in this cohort. The extent to which this may have affected our results is unknown, but its effect is expected to be limited. candidates, there is a growing need for accurate long-term risk models in the high-risk AVR population. Although investigation of the association between individual comorbidities and longterm survival is important, the interaction between these comorbidities is expected to be equally important for long-and short-term outcomes. While the current STS PROM calculator provides reasonable differentiation of long-term survival, a model calibrated to the prediction of long-term risk would be expected to add additional accuracy. Additionally, as previously discussed, the extent to which operative and perioperative management affects long-term outcomes remains incompletely understood. In particular, the comparative safety and effectiveness of valve prostheses and perioperative management strategies remain important topics for future investigation.
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Echocardiography
A ortic valve disease is common in the United States, occurring in 2% to 5% of the elderly population. 1 When untreated, symptom progression is both rapid 2-4 and lethal, [5] [6] [7] [8] with a median survival of �2 years in those with heart failure symptoms. 9 Medical therapy is largely ineffective for the long-term management of aortic valve disease, and valve replacement remains the standard of care in patients with an acceptable risk profile.
Clinical Perspective on p
Among the oldest patients and those with a high burden of comorbidities, the perioperative risk of surgical aortic valve replacement (AVR) is often perceived to outweigh the potential long-term benefits, with a perception of high operable risk accounting for nearly half (48%) of all nonoperated patients with symptomatic aortic stenosis. 10 Although the perioperative risk associated with AVR has been well studied, 11,12 the long-term outcomes after open AVR have not been well described, making accurate assessment of the benefits of open AVR challenging in this population.
Transcatheter delivery of aortic valve prostheses offers a potential treatment option in high-risk patients and has been shown at the 1-year follow-up to be both superior to medical therapy in nonoperable patients 13 and noninferior to open valve replacement in high-risk patients. 14 As long-term transcatheter AVR outcomes accrue, the establishment of a robust surgical benchmark of long-term survival after open AVR is of increasing importance to inform prognosis and to aid clinical and economic evaluations of new technologies.
To better inform this discussion, we linked clinical data from �1000 participating centers within the Society of Thoracic Surgeons (STS) network to Medicare administrative inpatient claims to create a large, well-characterized longitudinal cohort of elderly patients representative of those selected for AVR in the United States and Canada over the past 2 decades. Using this cohort, we sought to describe inhospital outcomes and long-term survival of open AVR and to assess the association between mortality and specific high-risk comorbidities, as well as the STS perioperative risk of mortality (PROM) score.
Methods
The STS Adult Cardiac Surgery Database (ACSD) is among the most robust clinical data repositories in the world, including �300 data elements describing patient demographics, comorbidities, and operative outcomes. The database began in 1989 with a mission to improve the quality of cardiac surgical procedures at participating centers. The ACSD now represents �1000 participants throughout North America, including �90% of cardiac surgery centers in the United States. 15 The ACSD maintains high standards of data accuracy, with a 96% correlation between ACSD data and data obtained through independent chart abstraction. 16 In partnership with the Duke Clinical Research Institute's Cardiovascular Outcomes Research Center, the STS has developed and validated a valve-specific morbidity and mortality operative risk calculator, 11 a tool that has been used to identify high-risk patients for inclusion in recent transcatheter AVR clinical trials. 13, 14 
Study Population
For the purposes of this study, STS ACSD records from 266 525 operations involving AVR procedures (with or without concomitant coronary artery bypass grafting [CABG]) in elderly patients (�65 years of age) were identified for linkage to Part A Medicare Provider and Analysis Review (MedPAR) insurance claims files (Figure 1 ). Records were excluded if they involved multiple valve procedures, other major non-valve-related operations (except CABG), prior AVR, and emergent or salvage operative status. With this method, 193 700 AVR procedures were identified for Medicare linkage. With the use of a previously validated linkage algorithm, 15, 17 indirect patient identifiers (eg, date of birth, age, admission date, discharge date, and hospital center) linked 145 911 STS ACSD records (75% linkage rate) to Part A MedPAR files submitted through December 2008. In the rare cases in which multiple Medicare records were matched to a single STS ACSD hospitalization, no linkage was made, and the case was excluded from the linked cohort. The resulting Medicare-linked STS ACSD AVR cohort included 145 911 patients undergoing procedures between 1991 and 2007 (maximum, 18 years of follow-up) with a minimum follow-up of 1 year. Because the proportion of missing data before 1999 was frequently high (�10%) for variables necessary to calculate the STS PROM score and because early outcomes of valve surgery are expected to have improved over the past 2 decades, a second, more contemporary Medicare-linked cohort was identified that included 103 500 patients undergoing procedures between 1999 and 2007 (maximum, 10 years of follow-up) with a minimum follow-up of 1 year. The 1991 to 2007 cohort was used to evaluate age-stratified very long-term outcomes after AVR; the 1999 to 2007 contemporary cohort was used to evaluate in-hospital complications and median survival stratified by the STS PROM and high-risk clinical features. Clinical characteristics and operative outcomes were tabulated and are presented for comparison of the Medicare-linked and Medicare-eligible STS ACSD AVR cohorts. The Duke University School of Medicine Institutional Review Board granted a waiver of informed consent and authorization for this study.
Patient Subgroups
Because long-term outcomes were expected to vary according to the burden of specific comorbidities, several patient subgroups were prospectively identified for analysis. For all analyses, patients were categorized by procedure type (eg, isolated AVR, AVR plus CABG) and age (65-69, 70 -79, �80 years). Other specific patient subgroups were categorized according to the STS data definitions for the following comorbidities: lung disease, left ventricular dysfunction (left ventricular ejection fraction �30%, �30%), renal failure, and prior cardiac operation (0, �1). According to the version 2.52 STS ACSD data specifications, lung disease was classified as follows: none, mild (forced expiratory volume in 1 second [FEV 1 ], 60%-75% of predicted and/or on long-term inhaled or oral bronchodilator therapy), moderate (FEV 1 , 50%-59% of predicted and/or on longterm steroid therapy aimed at lung disease), and severe (FEV 1 �50% predicted and/or room air PO 2 �60 mm Hg or room air PCO 2 �50 mm Hg). Renal failure was defined as a documented history of renal failure or a history of creatinine �2.0 mg/dL. Prior renal transplantation patients are not included as preoperative renal failure unless their creatinine has been �2.0 mg/dL since transplantation or is currently �2.0 mg/dL. For this analysis, the renal failure cohort was subdivided into those with and those without a preoperative need for dialysis. An STS PROM score was calculated using clinical data for each patient undergoing AVR between January 1999 and December 2007, and the cohort was stratified as low risk (�5% STS PROM), moderate risk (5%-9% STS PROM), and high risk (�10% STS PROM) using previously established cutoffs. 13, 14 Data necessary for classification of STS PROM were missing in �5% of patients in the contemporary cohort. Consistent with the standards of the STS PROM online calculator, missing values for body surface area were imputed to the sex-specific median value, and those for left ventricular ejection fraction were imputed to the sex-specific median value for patients with documented congestive heart failure or a "normal" value (ie, left ventricular ejection fraction�50%) for those without heart failure. Missing values for the remaining categorical risk factors were defaulted to their most common value (ie, "no disease").
Study End Point
Patient survival, which was the primary outcome of interest for this analysis, was assessed with the Medicare Denominator File included with MedPAR files. The Denominator File uses data from both the Social Security Administration Death Master File and other sources, including Medicare claims data, to ascertain dates of death for Medicare participants. The Denominator File is expected to be an accurate source of vital status for enrolled patients. 18 
Statistical Analysis
Demographics, comorbidities, and in-hospital outcomes were tabulated according to the procedure performed (eg, isolated AVR or AVR plus CABG) for both the complete AVR cohort (1991-2007; Table 1 ) and the contemporary AVR subgroup (1999 -2007; Table  2 ). In addition, to aid with assessment of the representativeness of the Medicare-linked STS ACSD AVR cohort compared with the overall Medicare-eligible STS ACSD AVR cohort, characteristics of each are presented in Table 1 . Baseline characteristics were summarized as percentages for categorical variables and as medians with 25th and 75th percentiles (interquartile range) for continuous variables.
Survival probabilities were calculated with the product-limit method of Kaplan and Meier, 19 and median survival was calculated as the time beyond which 50% of the cohort was expected to survive. Subgroup comparisons of Kaplan-Meier survival probabilities were made with log-rank tests. An estimate of discrimination of the STS PROM for 10-year survival in the contemporary AVR subgroup was calculated with the Harrell generalized c statistic for time-to-event data with censoring. SAS statistical software (version 9.1; SAS Institute, Cary, NC) was used for all calculations.
Results
Study Population
A cohort of 145 911 patients who underwent AVR from 1991 to 2007 at 1026 centers were linked to Medicare claims, including 61 530 who underwent isolated AVR and 84 381 who underwent AVR with concomitant CABG (Figure 1) . Characteristics of the full Medicare-linked cohort are described in Table 1 . Briefly, this was an elderly cohort (median age, 76 years) that included 40% women, with aortic stenosis present in 88%, chronic lung disease prevalent in 17%, renal failure seen in 6%, and prior cardiac operations present in 11%. Of the overall cohort, 58% presented with New York Heart Association class III or IV heart failure, and 46% presented with angina (including 28% of the isolated AVR cohort). Median follow-up was 6.4 years (interquartile range, 3.6 -10.8 years) with a maximum follow-up of 18 years.
Compared with cases that were not linked to Medicare, the Medicare-linked STS ACSD AVR cohort was similar across baseline patient characteristics, including both the isolated AVR and AVR plus CABG cohorts (Table 1) . Compared with the not linked cohort, those in the Medicare-linked isolated AVR cohort experienced a similar incidence of operative mortality (4.2% versus 4.0%), permanent stroke (2.0% versus 1.9%), and 30-day readmission (7.9% versus 8.3%). Likewise, the incidence of early complications after AVR plus CABG procedures was similar between the Medicare-linked and the not linked cohorts.
Of the full Medicare-linked AVR cohort, 103 500 patients underwent AVR from 1999 to 2007 at 962 centers (Figure 1 ). These patients formed our contemporary AVR cohort; this cohort included 43 809 patients who underwent isolated AVR and 59 691 who underwent AVR with concomitant CABG. Characteristics and in-hospital outcomes of the contemporary Medicare-linked AVR cohort (1999 -2007) were similar to those of the overall Medicare-linked AVR cohort (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) , except that those in the contemporary AVR cohort had a higher prevalence of chronic lung disease than those in the overall cohort (20.9% versus 16.5%). Median follow-up of the contemporary cohort was 4.7 years (interquartile range, 2.8 -6.8 years) with a maximum follow-up of 10 years.
In-Hospital Outcomes
In-hospital outcomes are presented in Table 2 for the contemporary Medicare-linked AVR cohort. The incidence of inhospital complications, postoperative length of stay, and operative mortality increased when the contemporary cohort was restricted to patients with an STS PROM �5% (moderate-and high-risk cohort) and �10% (high-risk cohort).
Long-Term Survival After Open AVR
Long-term survival after open AVR is presented in Figure 2 for the full Medicare-linked AVR cohort with stratification by patient age ( Figure 2A , isolated AVR; Figure 2B , AVR plus CABG). For patients 65 to 69, 70 to 79, and �80 years of age, the median survival after isolated AVR was 12.8, 9.2, and 6.2 years, respectively. For patients who received AVR with CABG, the median survival was 10.4, 8.2, and 5.9 years, respectively (Table 3) . Several specific patient characteristics (eg, lung disease, left ventricular dysfunction, renal failure, and prior cardiac operation) were associated with worse long-term survival after AVR (P�0.0001 comparing the survival probabilities of patients with no disease and no prior operation and those with disease or prior operation; Tables 4 and 5 ). Both severe lung disease and renal failure (especially dialysis-dependent renal failure) were associated with a particularly poor long-term prognosis.
The long-term survival of patients in the contemporary AVR cohort is presented in Figure 3 with stratification by age and STS PROM ( Figure 3A , isolated AVR; Figure 3B , AVR plus CABG). For both the isolated AVR and AVR plus CABG cohorts, long-term survival was effectively differentiated by STS PROM (c index, 0.72 at 1 year and 0.71 at 10 years), with worse long-term survival observed across strata of increasing STS PROM. Within the intermediate-risk (5%-9% STS PROM) and high-risk (�10% STS PROM) cohorts, long-term survival was similar across the spectrum of patient age. For example, among high-risk isolated AVR patients, the median postoperative survival for those 65 to 69, 70 to 79, and �80 years of age was 2.6, 2.5, and 2.7 years, respectively (Table 3) . However, among low-risk patients (�5% STS PROM), increasing patient age was associated with a further decrement in median survival.
Discussion
This report is the first of its kind to provide a detailed national contemporary benchmark of long-term survival after open AVR among elderly patients in the United States. From these results, 3 important findings emerge. First, despite advanced age, both the short-term prognosis and long-term prognosis of patients selected for open AVR remain favorable. Second, both severe lung disease and renal failure indicate a particularly poor long-term prognosis after open AVR. Finally, the STS PROM is an effective clinical tool for differentiating long-term survival after open AVR. Among moderate-and high-risk patients, patient age had limited incremental impact on long-term survival.
The expected survival in symptomatic patients with aortic valve disease is in the range of 2 to 3 years. 9 In light of this relatively short life expectancy, the long-term survival in elderly patients undergoing AVR or AVR with CABG is excellent. Although the median survival after isolated AVR in patients �70 years of age was lower than that of a similarly aged US population (13 years observed versus 16 years expected), 21 the median survival of patients �70 years of age was nearly equivalent to that of their peers 21 (9 versus 10 years for those 70 -79 years old and 6 years each for those �80 years old). Nevertheless, the long-term prognosis after AVR with concomitant CABG is somewhat worse than after isolated AVR. These findings are similar to the 20-year experience recently reported among octogenarians and nonagenarians undergoing open heart surgery at a single German hospital center, a cohort that included 303 isolated AVR and 297 AVR plus CABG procedures. 22 Among isolated AVR patients, the median survival was 6.1 years, which is nearly identical to survival reported here. As in our study, no difference was observed in median survival between the isolated AVR cohort and the age-and sex-matched population. In addition, as in our study, actuarial survival at 10 years in the AVR plus CABG cohort was lower than in the isolated AVR cohort (21.6% versus 18.2%; P�0.02). These data add further clarity to the results recently presented by Nkomo et al 1 that demonstrated reduced survival in a valvular heart disease cohort compared with an ageand sex-matched base population. Three notable differences are apparent between our cohort and the Nkomo et al cohort. First, the Nkomo et al population was a disease-based cohort that included patients not selected for AVR, whereas the STS population included only those patients who were selected for open AVR. Second, in addition to patients with aortic valve disease, the Nkomo et al cohort included patients with mitral valve disease (a cohort known to have worse survival). 23 Finally, in the Nkomo analysis, the Olmsted County cohort included a large subgroup (28%) of patients �65 years of age, a group that is anticipated to have a lower observed survival than expected from our data.
In addition to age, several specific risk factors (eg, lung disease, left ventricular dysfunction, renal failure, prior cardiac operation) were associated with reduced long-term survival, which is a finding similar to the results reported by others. 24 -26 Both severe lung disease and renal failure were associated with a nearly 50% lower observed 8-year survival compared with survival in patients without these comorbidities, whereas left ventricular dysfunction and prior cardiac operations were associated with a roughly 25% lower observed 8-year survival. Patients with dialysis-dependent renal failure had a particularly poor prognosis after isolated AVR, with a median survival of 2.5, 2.0, and 0.7 years among patients 65 to 69, 70 to 79, and �80 years of age, respectively. Importantly, this report expands on prior work by providing age-and comorbidity-stratified estimates of survival (median, 1, 4, and 8 years) that can be used directly for prognosis and to determine therapeutic options.
As shown in Figure 3 , the STS PROM was an effective means of differentiating long-term survival after open AVR. These results build on the single-center experience of Dewey et al, 27 who reported superior midterm (4.2�2.7 years; n�638) risk prediction of the STS PROM compared with both the EuroSCORE (additive and logistic) and Ambler Risk Score, especially among high-risk patients. In this multicenter cohort, we have demonstrated excellent differentiation of long-term risk among elderly patients using the STS PROM. Within the moderate-and high-risk strata of STS PROM, the observed operative mortality was similar across the spectrum of age, suggesting that the practice of "upgrading" clinical risk beyond that reported by the STS PROM calculator for the oldest patients is not necessary in these risk groups. Among low-risk patients, long-term survival was further stratified by patient age; however, the median survival among the oldest patients (�80 years old) with a low STS PROM was �7 years, both with and without concomitant CABG. Because these results may serve as a contemporary benchmark to evaluate new therapies (eg, transcatheter AVR and other novel valve prostheses), further comparison to the outcomes observed in the high-risk surgical arm of the Placement of Aortic Transcatheter Valve Trial (PARTNER) is merited. Between 2007 and 2009, a cohort of 351 patients undergoing isolated AVR at 22 high-volume centers in the United States and abroad were enrolled in the high-risk surgical arm of the PARTNER trial; they had a median�SD age of 84.5�6.4 years and a median�SD STS PROM of 11.7�3.5%. 14 In this cohort, the observed all-cause mortality at 30 days (6.5%) was substantially lower than expected (STS PROM observed-to-expected ratio, 0.68), and the 1-year survival was 73.2%. In comparison, the contemporary (1999 -2007) high-risk surgical cohort reported here had a median age of 81 years, an operative mortality of 17%, and a 1-year survival of 60% to 65%. Similarly, the 30-day incidence of stroke in the high-risk surgical arm of the PARTNER trial was 2.4% compared with a 4.0% incidence in the high-risk STS cohort, although the effects of differences in the stroke end-point definition and surveillance period between the STS ACSD and the PARTNER trial are unknown. The low incidence of operative complications and lower mortality observed in the PARTNER trial may have resulted from a general trend toward improved operative outcomes over time in the United States, from patient selection bias related to randomized clinical trial enrollment, or alternatively from superior outcomes at the PARTNER centers owing to unique perioperative processes of care and operative techniques. Further investigation may uncover important differences in care that could prompt a generalized improvement in operative outcomes.
Our study has 3 notable limitations. First, the linkage between STS and Medicare files is imperfect, resulting in the absence of long-term follow-up for one fourth of the STS elderly AVR cohort. Several contributing factors have been identified, including STS participation at centers that do not submit Medicare claims (eg, Kaiser, military, and non-US hospitals). However, the baseline characteristics and inhospital outcomes of linked and nonlinked elderly STS AVR patients are similar, increasing the likelihood that the results presented here are generalizable to the overall elderly STS AVR cohort. Second, the use of the Medicare Denominator File for ascertainment of long-term survival has known limitations inherent to the data source, 18 including an underreporting of mortality in some patient subgroups. This may have resulted in an overestimate of the true long-term survival of patients in this cohort. The extent to which this may have affected our results is unknown, but its effect is †P�0.0001 for each subgroup, comparing the survival probabilities of patients with no disease and no prior operation with those with disease or prior operation. ‡STS-PROM categories: low, �5%; moderate, 5% to 9.9%; and high, �10%. 14, 20 expected to be limited. Finally, although survival is a key component of the success of open AVR, functionality and independence may be equally important metrics of long-term success in this population. Proper evaluation of these outcomes would require an in-depth quality-of-life assessment, which remains beyond the scope of this investigation. While providing valuable insights into the real-world outcomes after open AVR, these results highlight the need for further investigation. In particular, because new transcatheter device protocols require an assessment of the likelihood of 1-year survival for potential candidates, there is a growing need for accurate long-term risk models in the high-risk AVR population. Although investigation of the association between individual comorbidities and long-term survival is important, the interaction between these comorbidities is expected to be equally important for long-and short-term outcomes. The current STS PROM calculator provides reasonable differentiation of long-term survival; however, a model calibrated to the prediction of long-term risk would be expected to add accuracy. Additionally, as previously discussed, the extent to which operative and perioperative management affects longterm outcomes remains incompletely understood. In particular, the comparative safety and effectiveness of valve prostheses and perioperative management strategies remain important topics for future investigation.
Conclusions
Long-term survival after open AVR is excellent, with survival after isolated AVR in patients �70 years of age matching that of a similarly aged US population. Long-term prognosis is well delineated by use of a combination of STS PROM and age, and both lung disease and renal failure (especially dialysis-dependent renal failure) are associated with a particularly poor long-term prognosis. Further investigation with this large multicenter cohort may improve long-term outcomes by helping to establish best practices in operative and perioperative care.
